Samsung Biologics lays out sustainability plans in new ESG report
The company says its goal is to reduce greenhouse gas emissions, limit waste, and increase social contributions in its new report
Samsung Biologics has laid out plans to reduce net greenhouse gas emissions and make its new Plant 4 more energy efficient in the company’s 2022 ESG Report, released this week.
The South Korean CDMO outlined a range of initiatives to address several environmental, social, and governance (ESG) activities related to its business. These include lowering greenhouse gas emissions, managing waste to protect local ecosystems, promoting corporate social responsibility, and promoting diversity and inclusion in its workforce.
The report highlights the company’s progress in reducing Scope 1 and 2 emissions by 32.3% compared to the previous year, and its commitment to reduce total Scope 1 and 2 emissions 54.3% and Scope 3 emissions 25.7% by 2026, compared to 2021. The company says it is also actively working to engage its suppliers to transition to net zero emissions in multiple areas and invest in renewable energy.
Samsung Biologics also laid out plans for its new Plant 4, which is due to be completed in 2023. It said the plant would become ‘the most energy-efficient, eco-friendly bio biopharmaceutical plant where solar panels and green refrigerants are implemented.’ When Plant 4 is completed, the company will have a production capacity of 620,000 liters in total, accounting for approximately 30% of the total global CMO production capacity.
Other environmental initiatives undertaken in recent months included replacing workplace lights with high-efficiency LED lights and building photovoltaic-based power facilities at the company’s Songdo site.
Samsung Biologics participates in the Frontier 1.5D initiative, which aims to develop a climate risk management model as part of the 2050 Carbon Neutral Strategy, as well as the Carbon Disclosure Project and the Health Systems Taskforce, part of His Royal Highness The Prince of Wales’ Sustainable Markets Initiative.
The report also detailed the separation of CEO and Chair positions in its Board structure and noted that outside directors were granted the right to request documentation.
Related News
-
News 5 big pharma companies agree to decarbonise operations in China
Following extensive talks, leading pharmaceutical companies sign an agreement to work with renewable energy companies to decarbonise their manufacturing supply chains in China and switch to renewables. -
News CPHI Podcast Series: The 2023 Retro – what have we learnt from the past year in pharma?
Welcome to the last episode of 2023! Digital Editor Lucy Chard is joined by her teammates in a special retrospective episode to close out the year. Guests Vivian Xie, Editor for CPHI Online and Tara Dougal, Content Director for Pharma, discuss their hi... -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Barcelona 2023 – From the Floor
It's that time of year again - the biggest pharma event of the year comes to Spain this October for CPHI Barcelona 2023. Follow our Editors Vivian Xie and Lucy Chard as they worked their way through the conference, bringing highlights from content ... -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News CPHI Barcelona Sustainability Partner Interview – Procaps' improvement through innovation
Procaps, developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents, has partnered with CPHI Barcelona to support sustainability initiatives, to be highlighted at t... -
News The future of robotics in pharma: drug discovery to manufacturing
Robotics are starting to play a key role in the discovery and manufacturing of health and drug products, with numerous benefits, from cost reduction to increased sustainability, but there are challenges as well. -
News CPHI Barcelona Sustainability Partner Interview – Rontis' mindful management
Rontis Corporation, a leading supplier in the healthcare industry worldwide, has partnered with CPHI Barcelona to support sustainability initiatives, to be highlighted at the CPHI Worldwide event in Barcelona in October 2023.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance